SOURCE: Mazal Plant Pharmaceuticals Inc.

October 11, 2006 18:00 ET

Mazal Plant Pharmaceuticals Inc. Announces Appointment of Richard Serbin as Head of Business Advisory Board

Business Veteran of Schering-Plough Corporation and Chief FDA Counsel for Johnson and Johnson Corporation to Assist With HDL Cholesterol Elevating Drug

NEW YORK, NY -- (MARKET WIRE) -- October 11, 2006 -- Mazal Plant Pharmaceuticals Inc. (PINKSHEETS: MZPP) (FRANKFURT: M9J) ("Mazal") announced today that Richard Serbin, who has served as Patent attorney for Schering Plough Corporation, Chief FDA Counsel for Revlon Corporation and Johnson and Johnson Corporation, President of Bradley Pharmaceuticals and founder of Radius Scientific Corporation, has been appointed as head of Mazal's Business Advisory Board. Mr. Serbin will play an active role in developing business strategy and joint venture contacts and in guiding the company in regulatory compliance and investor relations.

Richard Serbin commented, "I am pleased to have the opportunity to work with the management and scientists at Mazal to advance the understanding of this important lead product and assist in navigating the regulatory process required by the FDA for obtaining market approval for the botanical HDL cholesterol elevating drug, MAHDL. I am encouraged with the clinical results, which I have seen, and believe that this product offers the medical community a beneficial alternative to currently existing therapies. I am confident that both the investment community and the pharmaceutical industry will be interested in this product."

Dr. Mechael Kanovsky, President of Mazal Plant Pharmaceuticals Inc., said that, "We are confident that Mr. Serbin's experience in regulatory matters and connections with major pharmaceutical companies will be a major asset to the company in achieving its goals of completing clinical trials."

About Mazal Plant Pharmaceuticals Inc.

Mazal Plant Pharmaceuticals Inc. is an early-stage whole plant pharmaceutical development company whose mission is to develop treatments for chronic diseases from combinations of whole plants and to build shareholder value through negotiated relationships with strategic partners to fund commercialization and marketing of these treatments on a stand-alone or combination basis.

Additional information on Mazal Plant Pharmaceuticals Inc. may be found at:

Forward-Looking Statements

"Safe-Harbor'' Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes,'' "expects,'' "anticipates,'' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Mazal Plant Pharmaceuticals Inc. to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Mazal Plant Pharmaceuticals Inc.'s subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Mazal Plant Pharmaceuticals assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact Information

    LC group
    Rick Lutz
    (404) 261-1196